Sign in
Taking peoplePhase 3

Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 6-11 Months

Key facts

Who runs it
Sinovac Biotech Co., Ltd
Where
China2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 3
People taking part
1,040 people, planned
Started
22 Mar 2026
Expected to end
Jan 2028
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • experimental vaccine
  • Active Comparator vaccine
Record updated
10 August 2026

Who can take part

Age
6 months to 11 months
Sex
Women and men
Healthy volunteers
Can take part
Show the full registry criteria (21)Hide the full registry criteria

Who can take part

  • Healthy participants aged 6 to 11 months
  • The participant's legal guardian is capable of understanding and voluntarily signs the informed consent form
  • Willing and able to comply with all scheduled visits, sample collection, vaccination, and other trial procedures
  • Provision of legal identification documentation

Who cannot take part

  • Prior vaccination with any meningococcal vaccine (including but not limited to: Group A/C meningococcal polysaccharide/conjugate vaccine, ACYW135 meningococcal polysaccharide/conjugate vaccine, Group A meningococcal polysaccharide vaccine, etc.)
  • Receipt of immunosuppressants or other immunomodulatory therapy for ≥14 days (e.g., prednisone ≥20 mg/day or ≥2 mg/kg/day, or equivalent), cytotoxic therapy within the past 6 months, or planned receipt of such therapies during the study period
  • Receipt of any other investigational drug or vaccine within the past 3 months, or planned receipt during the study period
  • Receipt of a live attenuated vaccine within the past 14 days, or receipt of a subunit or inactivated vaccine within the past 7 days
  • Receipt of any other licensed vaccine within the past 28 days where administration at a different injection site from the study vaccine cannot be ensured
  • History (or suspected history) of meningococcal disease
  • Presence of autoimmune diseases, immunodeficiency diseases (including but not limited to asplenia, functional asplenia, HIV infection in the participant or the participant's mother), or current perianal abscess
  • Presence of poorly controlled chronic diseases or history of serious illnesses, including but not limited to cardiovascular diseases, hematological diseases, hepatorenal diseases, gastrointestinal diseases, respiratory diseases, malignancies, or history of major organ transplantation
  • Presence of or history of severe neurological disorders [epilepsy, convulsions or seizures], or family history of psychiatric disorders
  • Acute illness or acute exacerbation of chronic disease within the past 3 days, or known or suspected active infection
  • Any other condition that, in the investigator's judgment, makes the participant unsuitable for participation in this clinical trial
  • History of infantile wheezing; history of allergy to the vaccine or any vaccine components (Group A/C/Y/W135 meningococcal capsular polysaccharide, mannitol, sucrose, sodium dihydrogen phosphate monohydrate, disodium hydrogen phosphate dodecahydrate, sodium chloride, water for injection), such as urticaria, dyspnea, angioedema; or other serious adverse reactions following prior vaccination
  • Coagulation disorders (e.g., coagulation factor deficiency, platelet abnormalities) or history of significant bleeding, hematoma, or ecchymosis following intramuscular injection or venipuncture
  • Severe congenital anomalies, genetic defects, or malnutrition
  • Receipt of immunoglobulins or other blood products within the past 3 months, or planned receipt of such treatments during the study period
  • Fever (axillary temperature >37.0°C) on the day of scheduled study vaccination, or abnormal findings on physical examination that preclude vaccination
  • Skin lesions, inflammation, ulcers, rash, or scarring at the intended injection site that may interfere with vaccination or local reaction assessment

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Epidemic meningitis or meningococcal vaccines

This trial is currently available in China.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this clinical trial is to evaluate the immunogenicity, safety, and persistence of the immune response of a group ACYW135 meningococcal conjugate vaccine in healthy children aged 6 to 11 months.

Read full original descriptionShow less

The main questions it aims to answer are:

Is the immune response induced by the investigational vaccine non-inferior to that of the licensed control vaccine following the primary series? What is the safety profile of the investigational vaccine during the primary series and booster dose? Does the investigational vaccine provide durable immune persistence up to 18 months of age? What is the immunogenicity of a booster dose administered at 18 months of age? Researchers will compare the investigational vaccine group with the active comparator group (licensed group ACYW135 meningococcal conjugate vaccine (CRM197 carrier), CanSinoBIO) during the primary immunization phase. Only the investigational group will receive a booster dose at 18 months of age to evaluate booster immunogenicity and safety.

Participants will:

Be randomly assigned in a 1:1 ratio to receive either two doses of the investigational vaccine or two doses of the control vaccine according to a 0,1-month schedule during the primary immunization phase; In the investigational group only, receive a booster dose at 18 months of age; Provide blood samples at three time points: before primary vaccination, 30 days after primary vaccination, and at 18 months of age to assess primary immunogenicity and immune persistence; In the investigational group only, provide an additional blood sample 30 days after the booster dose to assess booster immunogenicity; Be observed for 30 minutes after each dose for immediate adverse reactions; Have solicited local and systemic adverse events recorded for 7 days after each dose using diary cards; Have unsolicited adverse events recorded for 30 days after each dose using diary cards; Be monitored for serious adverse events for at least 6 months after the last dose administered; A total of 1040 participants will be enrolled.

The 2 groups in the trial

  • experimental groupTreatment being tested

    Treatment: experimental vaccine

  • active comparator groupExisting treatment, for comparison

    Treatment: Active Comparator vaccine

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 1 eligibility question with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized, Double-Blind, Active Comparator-Controlled Phase Ⅲ Trial to Evaluate the Immunogenicity and Safety of the Group ACYW135 Meningococcal Conjugate Vaccine in Population Aged 6 to 11 Months
Criteria questions
Built from NCT07505823, who can take part
Record updated
10 August 2026